CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
Hiroyuki Okamoto, Nathanael L. Dirks, Maria Rosario, Tetsuharu Hori, Toshifumi Hibi
Intest Res. 2021;19(1):95-105.   Published online July 10, 2020
DOI: https://doi.org/10.5217/ir.2019.09167

Excel Download

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
Intestinal Research. 2021;19(1):95-105   Crossref logo
Link1 Link2 Link3

Biological Therapy of Crohn’s Disease: Natalizumab, Vedolizumab, and Anti-MadCAM
Crohn's Disease and Ulcerative Colitis. 2017;375-380   Crossref logo
Link1

Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
BioDrugs. 2014;29(1):57-67   Crossref logo
Link1 Link2 Link3

Erratum to: Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
BioDrugs. 2015;29(1):73-73   Crossref logo
Link1 Link2 Link3

Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis
Journal of Crohn's and Colitis. 2020;14(8):1066-1073   Crossref logo
Link1 Link2 Link3

Improving Quality of Care in Inflammatory Bowel Disease Through Patients’ Eyes: IQCARO Project
Inflammatory Bowel Diseases. 2019;26(5):782-791   Crossref logo
Link1 Link2

P441 Long-term immunogenicity of vedolizumab in ulcerative colitis and Crohn’s disease (GEMINI Programme)
Journal of Crohn's and Colitis. 2019;13(Supplement_1):S331-S331   Crossref logo
Link1

What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?
Inflammatory Bowel Diseases. 2018;24(5):953-959   Crossref logo
Link1

The role of vedolizumab in patients with moderate-to-severe Crohn’s disease and ulcerative colitis
Therapeutic Advances in Gastroenterology. 2016;9(3):330-338   Crossref logo
Link1 Link2 Link3

Biologic Therapy of Ulcerative Colitis: Natalizumab, Vedolizumab, Etrolizumab (rHUMab Beta 7), Anti-MAdCAM
Crohn's Disease and Ulcerative Colitis. 2017;449-454   Crossref logo
Link1